Skip to main content
. 2015 Oct 7;2015(10):CD010081. doi: 10.1002/14651858.CD010081.pub2

EUCTR2006‐005405‐67.

Methods This is a parallel group RCT
Participants The trial included adults aged 18 to 64 with Hurley stage I to II HS
Interventions

  • Oral zinc 90 mg daily versus placebo
Outcomes

  1. Percentage of participants with at least a 75% reduction in HS lesion number at 3 months compared with baseline
Notes The trial was registered in 2007; we are uncertain if it has been completed